REAL SCIENCE. REAL POSSIBILITIES.A naturally occurring copper peptide with long-standing research interest around skin quality, collagen, hair and tissue repair.
GHK-Cu is best known as a copper peptide for skin, collagen, hair and tissue repair. Its long history in cosmetic and wound-healing research gives it a broader story than many newer research peptides.
These cards show what GHK-Cu is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
Skin repair is one of the longest-standing reasons for interest in GHK-Cu, including how damaged or ageing skin recovers and renews itself.
Laboratory, animal and some human topical studies have explored wound repair, skin appearance and the rebuilding of supporting skin tissue.
GHK-Cu is frequently associated with collagen and the supporting structure that helps give skin its firmness and resilience.
Laboratory studies suggest effects on genes and repair processes involved in collagen and the surrounding tissue structure.
Cosmetic interest centres on smoother texture, firmness and the visible changes associated with sun exposure and ageing.
Some small human studies and product-specific data are encouraging, although the evidence is not strong enough to support every anti-ageing claim made for copper peptides.
GHK-Cu also appears in discussions and products aimed at supporting the scalp and encouraging healthier-looking hair.
There are plausible biological reasons for the interest, but strong clinical evidence for meaningful hair regrowth is still limited.
GHK-Cu is best known as a copper peptide for skin, collagen, hair and tissue repair. Its long history in cosmetic and wound-healing research gives it a broader story than many newer research peptides.
Laboratory, animal and some human topical studies have explored wound repair, skin appearance and the rebuilding of supporting skin tissue.
Laboratory studies suggest effects on genes and repair processes involved in collagen and the surrounding tissue structure.
Some small human studies and product-specific data are encouraging, although the evidence is not strong enough to support every anti-ageing claim made for copper peptides.
There are plausible biological reasons for the interest, but strong clinical evidence for meaningful hair regrowth is still limited.
Patients undergoing circumoral CO2 laser skin resurfacing
Normal human fibroblasts in culture
Published topical GHK / GHK-Cu research
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
Recurring themes from peptide and wellness communities, shown alongside what published research currently suggests.
GHK-Cu attracts interest because skin quality, collagen, wound repair and hair health form a coherent story. The most credible practical evidence is topical and product-specific; injectable routines are much less characterised.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
Small topical and post-procedure studies provide limited human support, but formulations and outcomes vary.
Cell research links GHK-Cu with extracellular-matrix, collagen and repair-related signalling.
Promising for topical skin research, but broad anti-ageing claims remain ahead of the evidence.
Human evidence is mainly product- and procedure-specific rather than a general healing treatment programme.
Laboratory work supports effects on fibroblasts, matrix biology and repair signalling.
Biologically credible, with limited direct clinical proof for most everyday uses.
Robust controlled evidence for meaningful hair regrowth is limited.
Copper-peptide and follicle biology offer a rationale, but do not establish a predictable result.
An active area of interest rather than an established hair-loss treatment.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toGHK-Cu, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
Human research is mainly topical and product-specific; there is no validated general injectable GHK-Cu dosing protocol in the evidence set.
Patients after circumoral CO2 laser resurfacing
Published study structure, shown as data — not a personal dosing schedule.
Product-specific research protocol; not a general dosing recommendation.
Topical use is usually discussed by product strength and directions. Injectable discussions often begin around 1 mg per day, but no human dose-finding study validates that starting amount.
Four-to-eight-week topical or injected courses are commonly described. Formulation, route and absorbed exposure are not interchangeable.
Intermittent topical use is widely discussed; there is no validated injectable maintenance dose, cycle or break interval.
Topical use is much more commonly supported and discussed. Injectable subcutaneous use also appears in peptide communities but is less established.
When injectable use is discussed, routine subcutaneous sites are more typical than targeted injection into skin, scalp or injured tissue. Evidence for a local injection advantage is lacking.
No consistent injection timing pattern has strong support; community discussion tends to focus more on repeated exposure than a particular time of day.
Multi-week courses are discussed, but injectable GHK-Cu lacks a validated human dosing framework for cosmetic or repair uses.
Much of the stronger human interest in GHK-Cu relates to topical or local skin products. Injectable community use should not be assumed to share the same evidence base.
Community reports describe what people say they do; they are not instructions, validated protocols, or evidence that a particular injection site or timing improves outcomes.The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
A worsening wound, spreading redness, fever or a severe skin reaction needs medical assessment rather than continued experimentation.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
Published human work is mainly topical and formulation-specific. It does not establish an authorised injectable GHK-Cu treatment schedule.
Topical clinical study · PubMed ↗Cosmetic serum, wound-care formulation and injectable product cannot be treated as equivalent exposures.
Topical evidence review · PubMed ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.